380 related articles for article (PubMed ID: 8646825)
1. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans.
Gramatté T; Oertel R; Terhaag B; Kirch W
Clin Pharmacol Ther; 1996 May; 59(5):541-9. PubMed ID: 8646825
[TBL] [Abstract][Full Text] [Related]
2. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil.
Gramatté T; Oertel R
Clin Pharmacol Ther; 1999 Sep; 66(3):239-45. PubMed ID: 10511059
[TBL] [Abstract][Full Text] [Related]
3. Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.
Schwarz UI; Gramatté T; Krappweis J; Berndt A; Oertel R; von Richter O; Kirch W
Clin Pharmacol Ther; 1999 Mar; 65(3):283-90. PubMed ID: 10096260
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound.
Spahn-Langguth H; Baktir G; Radschuweit A; Okyar A; Terhaag B; Ader P; Hanafy A; Langguth P
Int J Clin Pharmacol Ther; 1998 Jan; 36(1):16-24. PubMed ID: 9476144
[TBL] [Abstract][Full Text] [Related]
5. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein.
Westphal K; Weinbrenner A; Giessmann T; Stuhr M; Franke G; Zschiesche M; Oertel R; Terhaag B; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2000 Jul; 68(1):6-12. PubMed ID: 10945310
[TBL] [Abstract][Full Text] [Related]
6. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.
Westphal K; Weinbrenner A; Zschiesche M; Franke G; Knoke M; Oertel R; Fritz P; von Richter O; Warzok R; Hachenberg T; Kauffmann HM; Schrenk D; Terhaag B; Kroemer HK; Siegmund W
Clin Pharmacol Ther; 2000 Oct; 68(4):345-55. PubMed ID: 11061574
[TBL] [Abstract][Full Text] [Related]
7. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers.
Han Y; Guo D; Chen Y; Tan ZR; Zhou HH
Xenobiotica; 2009 Sep; 39(9):694-9. PubMed ID: 19555315
[TBL] [Abstract][Full Text] [Related]
8. Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol.
Schwarz UI; Hanso H; Oertel R; Miehlke S; Kuhlisch E; Glaeser H; Hitzl M; Dresser GK; Kim RB; Kirch W
Clin Pharmacol Ther; 2007 May; 81(5):669-78. PubMed ID: 17392718
[TBL] [Abstract][Full Text] [Related]
9. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo.
Wetterich U; Spahn-Langguth H; Mutschler E; Terhaag B; Rösch W; Langguth P
Pharm Res; 1996 Apr; 13(4):514-22. PubMed ID: 8710739
[TBL] [Abstract][Full Text] [Related]
10. Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat.
Shirasaka Y; Kuraoka E; Spahn-Langguth H; Nakanishi T; Langguth P; Tamai I
J Pharmacol Exp Ther; 2010 Jan; 332(1):181-9. PubMed ID: 19779132
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans.
Schwarz UI; Gramatté T; Krappweis J; Oertel R; Kirch W
Int J Clin Pharmacol Ther; 2000 Apr; 38(4):161-7. PubMed ID: 10783825
[TBL] [Abstract][Full Text] [Related]
12. Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans.
Tubic M; Wagner D; Spahn-Langguth H; Weiler C; Wanitschke R; Böcher WO; Langguth P
Eur J Pharm Sci; 2006 Nov; 29(3-4):231-9. PubMed ID: 16713700
[TBL] [Abstract][Full Text] [Related]
13. Site-dependent small intestinal absorption of ranitidine.
Gramatté T; el Desoky E; Klotz U
Eur J Clin Pharmacol; 1994; 46(3):253-9. PubMed ID: 8070507
[TBL] [Abstract][Full Text] [Related]
14. Circadian variations in exsorptive transport: in situ intestinal perfusion data and in vivo relevance.
Okyar A; Dressler C; Hanafy A; Baktir G; Lemmer B; Spahn-Langguth H
Chronobiol Int; 2012 May; 29(4):443-53. PubMed ID: 22489638
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of bicarbonate absorption and its relationship to sodium transport in the human jejunum.
Turnberg LA; Fordtran JS; Carter NW; Rector FC
J Clin Invest; 1970 Mar; 49(3):548-56. PubMed ID: 5415681
[TBL] [Abstract][Full Text] [Related]
16. Griseofulvin absorption from different sites in the human small intestine.
Gramatté T
Biopharm Drug Dispos; 1994 Dec; 15(9):747-59. PubMed ID: 7888603
[TBL] [Abstract][Full Text] [Related]
17. The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen.
Weitschies W; Bernsdorf A; Giessmann T; Zschiesche M; Modess C; Hartmann V; Mrazek C; Wegner D; Nagel S; Siegmund W
Pharm Res; 2005 May; 22(5):728-35. PubMed ID: 15906167
[TBL] [Abstract][Full Text] [Related]
18. Effect of bifendate on the pharmacokinetics of talinolol in healthy subjects.
Zeng Y; He FY; He YJ; Dai LL; Fan L; Zhou HH
Xenobiotica; 2009 Nov; 39(11):844-9. PubMed ID: 19845435
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein and surfactants: effect on intestinal talinolol absorption.
Bogman K; Zysset Y; Degen L; Hopfgartner G; Gutmann H; Alsenz J; Drewe J
Clin Pharmacol Ther; 2005 Jan; 77(1):24-32. PubMed ID: 15637528
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers.
Krueger M; Achenbach H; Terhaag B; Haase H; Richter K; Oertel R; Preiss R
Int J Clin Pharmacol Ther; 2001 Feb; 39(2):61-6. PubMed ID: 11270803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]